No Data
No Data
Shanwaishan (688410.SH): The company's distribution is based on a buyout distribution model.
On September 10, Gelonghui disclosed the investor relations activity record of Shanwaishan (688410.SH), showing that Shanwaishan Company's continuity blood purification equipment (CRRT) sales in China adopt a combination of direct sales and distribution, with distribution as the main mode. The company's distribution is a buyout distribution model, without the situation of equipment placement. Shanwaishan Company's self-developed continuous blood purification pipeline is a special consumable for the company's SWS-5000 equipment (CRRT), belonging to a closed system. With the increase in the company's CRRT equipment market share, as well as the improvement in startup rate and frequency of use, it will drive.
Why SWS Hemodialysis Care's (SHSE:688410) Soft Earnings Are Just The Beginning Of Its Problems
The Return Trends At SWS Hemodialysis Care (SHSE:688410) Look Promising
Half-year report for the year 2024.
Summary of Half-Year Report in 2024.
The price of the transfer by inquiry this time for Shandong Laobaixing Pharmacy Chain Co., Ltd. (688410.SH) is RMB 10.02 per share.
On August 15th, Gelunhui reported that the transfer price for this inquiry was 10.02 yuan per share, with a transfer quantity of 7,068,945 shares. The controlling shareholder, actual controller, directors, supervisors, and senior management personnel of the company did not participate in this inquiry transfer.
No Data
No Data